期刊文献+

玻璃体手术治疗增殖性糖尿病视网膜病变临床分析 被引量:3

Observation and analysis of vitrectomy for the treatment of proliferative diabetic retinopathy
原文传递
导出
摘要 目的观察手术治疗增殖性糖尿病视网膜病变的治疗效果。方法对2007~2012年期间在焦作煤业集团中央医院眼科接受玻璃体手术治疗的增殖性糖尿病视网膜病变患者95例(116只眼)进行回顾性分析。入选病例分为3组:第1组为单纯玻璃体积血,第2组为纤维血管性增殖合并局限性视网膜脱离但未累及黄斑组,第3组为视网膜脱离累及黄斑组。对以上3组病例术前术后最佳矫正视力进行统计学分析。结果第1组术后最佳矫正视力改善率为78.9%;第2组术后最佳矫正视力改善率为80.0%;第3组手术后最佳矫正视力改善率为53.5%。第1组与第2组的视力改善情况经,检验,差异无统计学意义(P=0.911);第3组视力改善情况与第1组、第2组比,差异有统计学意义(尸值分别为0.016、0.014)。结论在黄斑未明显受累时,玻璃体手术治疗增殖性糖尿病视网膜病变可获得较为理想的视力预后。 Objective To investigate the therapeutic effect of vitrectomy for the treatment of pro-liferative diabetic retinopathy. Methods The data of 95 cases (116 eyes) with PDR who had accept-ed vitrectomy in our hospital during 2007 and 2012 were retrospectively analyzed. The cases were divided into three groups: the patients in group one had simple vitreous hemorrhage without retinal detachment; group two with fiber vascular proliferation combined retinal detachment but uninvolved macular; group three with retinal detachment and involved macular. The above three groups of cases pre-and post-operative corrected vision was analyzed statistically. Results The improvement rate of best corrected visual acuity postoperative period in group one was 78.9%, group two 80.0%, group three 53.5%. There were no statistical differences in the best corrected visual acuity between group one and group two (P =0.911); while significant difference between group three and group one and group two (P =0.016, 0.014). Conclusions When the macular is not involved obviously, the pa- tients with PDR will obtain a relatively ideal visual prognosis.
出处 《中国实用眼科杂志》 CSCD 北大核心 2013年第9期1153-1154,共2页 Chinese Journal of Practical Ophthalmology
关键词 玻璃体手术 增殖性糖尿病视网膜病变 Vitrectomy Proliferative diabetic retinopathy
  • 相关文献

参考文献7

二级参考文献25

  • 1高立新,张薇.增殖性糖尿病视网膜病变的玻璃体手术治疗[J].中国实用眼科杂志,2005,23(1):55-58. 被引量:37
  • 2徐景美,陈惠茹,徐冰,肖林,张新成.糖尿病性视网膜病变的手术时机及疗效的探讨[J].眼外伤职业眼病杂志,2005,27(4):266-268. 被引量:14
  • 3黎晓新.糖尿病眼病的防治要重视综合治疗[J].眼科,2005,14(4):214-217. 被引量:16
  • 4卢海,张风.晶状体超声乳化联合玻璃体手术治疗合并白内障的增生性糖尿病视网膜病变[J].眼科,2006,15(3):198-201. 被引量:19
  • 5Munir WM, Pulido JS, Shanna MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy[J]. Can J Ophthalmol,2005,40(5 ) :598-504.
  • 6Bahar I,Axer-Siegel R, Weinberger D. Pars plana vitrectomy: comparison of three techniques for the treatment of diabetic vitreous hemorrhage [J].Ophthalmic Surg Lasers Imaging, 2006, 37 (5) :364-369.
  • 7The Diabetic Retinopathy Vitreetomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 2[J].Arch Ophthalmol, 1985,103 ( 11 ) :1644-1652.
  • 8Machemer R,Buettner H,Norton EWD,et al.Vitrectomy:a pars plans approach.Trans Am Acad Ophthalmol Otolaryngol,1971,75:813-820.
  • 9Diabetic Retinopathy Vitrectomy Study Research Group.Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management,Diabetic Retinopathy Vitrectomy Study report I.Ophthalmology,1985,92:492-502.
  • 10de Bustros S,Thompson JT,Michels RG,et al.Vitrectomy for progressive proliferative diabetic retinopathy.Arch Ophthalmol,1987,105:196-199.

共引文献21

同被引文献33

  • 1黎明,赵铁英,秦波,姚茂兴.硅油填充下牵引性视网膜脱离的手术治疗[J].中国实用眼科杂志,2005,23(7):673-675. 被引量:11
  • 2Hayes RP, Curtis B, Ilag L, et al . Expectations about insulin therapy, perceived insulin- delivery system social acceptability, and insulin treatment satisfaction contribute to decreases in insulin therapy self-efficacy in patients with type 2 diabetes after 36 weeks insulin therapy. J Diabetes 2013 ;5 (3) :358-367.
  • 3Vichayanrat A, Matawaran B J, Wibudi A, et al . Assessment of basehne characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: the Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study. J D/abetes 2013;5(3):309-318.
  • 4Yeoh J, Williams C, Allen P, et al. Avastin as an adjunct to vitreetomy in the management of severe proliferative diabetic retinopathy : a prospective ease series. Clin Experiment Ophthalmol 2008 ;36(5):449-454.
  • 5Issa SA,Connor A,Habib M,et al. Comparison of retinal breaksobserved during 23 gauge transconjunctival vitrectomy versus con-ventional 20 gauge surgery for proliferative diabetic retinopathy[J]. Clin Ophthalmol, 2011,5 (1) : 109-114. DOI: 10.2147/OPTH. S16414.
  • 6Ishikawa K, Yoshida S, Nakao S, et al. Periostin promotes thegeneration of fibrous membranes in proliferative vitreoretinopathy[J]. FASEB J, 2014,28 (1): 131-142. DOI; 10. 1096/fj.13-229740.
  • 7Garweg JG, Tappeiner C, Halberstadt M. Pathophysiology of pro-liferative vitreoretinopathy in retinal detachment [ J ]. Surv Oph-thalmol, 2013,58 (4) : 321-329. DOI: 10.1016/j. survophthal.2012.12.004.
  • 8Ghasemi Falavaijani K, Modarres M. Proliferative vitreoretinopa-thy and antivascular endothelial growth factor treatment [ J]. Eye(Lend), 2014,28 (12): 1525-1526. DOI: 10. 1038/eye.2014.199.
  • 9Priglinger CS, Priglinger S. Pharmacological approach to treatmentof proliferative vitreoretinopathy [ J ]. Ophthalmologe,2013, 110(10): 948-959. DOI: 10.1007/s00347-013-2832-z.
  • 10Pastor JC, Rojas J, Pastor-Idoate S. et al. Proliferative vitreoreti-nopathy :A new concept of disease pathogenesis and practical con-sequences [J ]. Prog Retin Eye Res, 2015, [ Epub ahead ofprint]. DOI: 10.1016/j. preteyeres. 2015.07.005.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部